Literature DB >> 11861869

Construction of a human immunodeficiency virus type 1 (HIV-1) library containing random combinations of amino acid substitutions in the HIV-1 protease due to resistance by protease inhibitors.

Keisuke Yusa1, Wei Song, Matthias Bartelmann, Shinji Harada.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) heterogeneity contributes to the emergence of drug-resistant virus, escape from host defense systems, and/or conversion of the cellular tropism. To establish an in vitro system to address a heterogeneous virus population, we constructed a library of HIV-1 molecular clones containing a set of random combinations of zero to 11 amino acid substitutions associated with resistance to protease inhibitors by the HIV-1 protease. The complexity (2.1 x 10(5)) of the HIV-1 library pNG-PRL was large enough to cover all of the possible combinations of zero to 11 amino acid substitutions (a total of 4,096 substitutions possible). The T-cell line MT-2 was infected with the HIV-1 library, and resistant viruses were selected after treatment by the protease inhibitor ritonavir (0.03 to 0.30 microM). The viruses that contained three to eight amino acid substitutions could be selected within 2 weeks. These results demonstrate that this HIV-1 library could serve as an alternative in vitro system to analyze the emergence of drug resistance and to evaluate the antiviral activity of novel compounds against multidrug-resistant viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861869      PMCID: PMC135978          DOI: 10.1128/jvi.76.6.3031-3037.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

Authors:  K Yoshimura; R Kato; K Yusa; M F Kavlick; V Maroun; A Nguyen; T Mimoto; T Ueno; M Shintani; J Falloon; H Masur; H Hayashi; J Erickson; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

Review 2.  The HIV-1 protease as a therapeutic target for AIDS.

Authors:  C Debouck
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

3.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene.

Authors:  J Kimpton; M Emerman
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

Review 4.  Retroviral proteinases.

Authors:  S Oroszlan; R B Luftig
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

5.  High efficiency transformation of Escherichia coli with plasmids.

Authors:  H Inoue; H Nojima; H Okayama
Journal:  Gene       Date:  1990-11-30       Impact factor: 3.688

Review 6.  HIV drug resistance.

Authors:  D D Richman
Journal:  Annu Rev Pharmacol Toxicol       Date:  1993       Impact factor: 13.820

7.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

8.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

9.  Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.

Authors:  A H Kaplan; J A Zack; M Knigge; D A Paul; D J Kempf; D W Norbeck; R Swanstrom
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

10.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

View more
  2 in total

1.  Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors.

Authors:  Mako Toyoda; Yoko Ogata; Macdonald Mahiti; Yosuke Maeda; Xiaomei T Kuang; Toshiyuki Miura; Heiko Jessen; Bruce D Walker; Mark A Brockman; Zabrina L Brumme; Takamasa Ueno
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 2.  Enhancing protein backbone binding--a fruitful concept for combating drug-resistant HIV.

Authors:  Arun K Ghosh; David D Anderson; Irene T Weber; Hiroaki Mitsuya
Journal:  Angew Chem Int Ed Engl       Date:  2012-01-31       Impact factor: 15.336

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.